5 Value Stocks to Watch: MRNA, QQQ, Intel, Nebius, SpaceX

For market participants, this August 19 screen is less a definitive buy list than a map of where value-labeled dollar volume clustered in recent sessions. The presence of an ETF and a private company alongside tradable equities signals that screen outputs can be noisy, making the underlying classification methodology as important as the names themselves.

On August 19, 2026, MarketBeat's stock screener surfaced Moderna (MRNA), Invesco QQQ (QQQ), SpaceX, Intel (INTC), and Nebius Group (NBIS) as the five Value stocks with the highest dollar trading volume over the last several days. A companion large-cap screen for the same date separately highlighted Moderna (MRNA), SanDisk (SNDK), and Micron Technology (MU). Because the underlying sources are syndicated screener outputs rather than independently reported analysis or valuation studies, the takeaway is not that these names are definitively undervalued. Instead, the list shows which securities classified under a value methodology attracted the most dollar turnover, a liquidity signal that may precede repositioning but does not by itself prove fundamental quality.

“

On August 19, 2026, MarketBeat's stock screener surfaced Moderna (MRNA), Invesco QQQ (QQQ), SpaceX, Intel (INTC), and Nebius Group (NBIS) as the five Value stocks with the highest dollar trading volume over the last several days.

Value investing traditionally relies on metrics such as price-to-earnings ratios, book value, cash flow, and dividend yield to identify companies trading below intrinsic worth. Yet the MarketBeat screener described here ranks by dollar trading volume within a pre-defined value universe, not by a disclosed valuation threshold. That nuance is critical: a high-volume value screen captures investor attention and potential mean-reversion candidates, but it can also include names whose value labels are inconsistent with their economic profiles.

Moderna is the most instructive crossover name. It appears on both the value and large-cap high-volume lists, reflecting a stock that has transitioned from pandemic-era COVID vaccine revenue to a diversified messenger RNA platform. The source description enumerates a deep pipeline spanning respiratory vaccines (COVID-19, influenza, RSV, hMPV/PIV3), latent vaccines (CMV, Epstein-Barr, HSV, varicella zoster, HIV), public health vaccines (Zika, Nipah, Mpox), and infectious disease vaccines such as Lyme and norovirus. That breadth is strategically meaningful, but biotech companies rarely fit the traditional value definition because their future earnings hinge on binary trial outcomes, regulatory approval, and commercial uptake rather than stable cash flows. Thus, Moderna's presence in a value screen should be read as a possible valuation reset relative to past growth expectations rather than a classic low-multiple, dividend-paying stalwart.

Invesco QQQ is not an operating company; it is a unit investment trust designed to track the Nasdaq-100 Index. Including an ETF in a value equities screen is an immediate category red flag. While the trust does provide diversified exposure, its benchmark is dominated by technology and communications companies that often trade at growth multiples. An investor using the value screen with the expectation of buying a single undervalued company would be buying an index product instead. The dollar-volume ranking may simply reflect QQQ's status as one of the most heavily traded equity products in the market, not evidence of a value opportunity in the underlying Nasdaq-100 constituents.

SpaceX presents an even more fundamental data-quality problem. The company is privately held and does not have a publicly traded common stock, despite the screen listing it among Value stocks to watch. This likely stems from how data vendors assign entity records or how the screener's value universe is constructed, but it is a reminder that screen outputs are only as good as their reference data. No dollar volume figure for individual SpaceX shares can exist in a public market, so the inclusion should not be acted upon as a tradable value equity.

Intel and Nebius represent two different types of potential value or turnaround stories. Intel, a legacy semiconductor giant, has been through a difficult period of market share erosion, advanced-node delays, and a costly foundry strategy. It is plausible that its stock screens as value-like on asset or book-based measures even as earnings are depressed; the screener's high dollar volume indicates traders are actively repositioning. Nebius, by contrast, is an AI-infrastructure company that has drawn speculative interest amid accelerating demand for compute capacity. Its inclusion in a value screen may reflect a gap between current infrastructure spending and eventual revenue, rather than a stable free-cash-flow profile.